Osimertinib in Advanced Non–Small-Cell Lung Cancer

Cancer Topics - Contrasting Cases: EGFR Mutant NSCLCПодробнее

Cancer Topics - Contrasting Cases: EGFR Mutant NSCLC

Osimertinib and chemotherapy in EGFR+ lung cancer with TP53 and RB1 alterationsПодробнее

Osimertinib and chemotherapy in EGFR+ lung cancer with TP53 and RB1 alterations

Osimertinib with Chemotherapy in EGFR-Mutated NSCLC | NEJMПодробнее

Osimertinib with Chemotherapy in EGFR-Mutated NSCLC | NEJM

Osimertinib in Advanced Non–Small Cell Lung CancerПодробнее

Osimertinib in Advanced Non–Small Cell Lung Cancer

Arun Krishna, AstraZeneca: TAGRISSO® Proven Effective at Treating Non-Small Cell Lung CancerПодробнее

Arun Krishna, AstraZeneca: TAGRISSO® Proven Effective at Treating Non-Small Cell Lung Cancer

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinibПодробнее

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinib

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLCПодробнее

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLC

Expert video report on combination treatments in first-line oncogene addicted advanced NSCLCПодробнее

Expert video report on combination treatments in first-line oncogene addicted advanced NSCLC

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLCПодробнее

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

2023 Best of Lung: Targeted Therapies in Lung CancerПодробнее

2023 Best of Lung: Targeted Therapies in Lung Cancer

Tagrisso (osimertinib)- non-small cell lung cancer (NSCLC)Подробнее

Tagrisso (osimertinib)- non-small cell lung cancer (NSCLC)

ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trialПодробнее

ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial

Osimertinib resistance in non-small cell lung cancer: Pathways and potential solutionsПодробнее

Osimertinib resistance in non-small cell lung cancer: Pathways and potential solutions

Dr Karthik S | Udupa Real world Evidence Osimertinib as SoC in the management of EGFRm NSCLCПодробнее

Dr Karthik S | Udupa Real world Evidence Osimertinib as SoC in the management of EGFRm NSCLC

Tagrisso (Osimertinib): Past, Present, and Lung-itudinal Future Role in Non-Small Cell Lung Cancer 3Подробнее

Tagrisso (Osimertinib): Past, Present, and Lung-itudinal Future Role in Non-Small Cell Lung Cancer 3

Tagrisso (Osimertinib): Past, Present, and Lung-itudinal Future Role in Non-Small Cell Lung Cancer 2Подробнее

Tagrisso (Osimertinib): Past, Present, and Lung-itudinal Future Role in Non-Small Cell Lung Cancer 2

Tagrisso (Osimertinib): Past, Present, and Lung-itudinal Future Role in Non-Small Cell Lung Cancer 1Подробнее

Tagrisso (Osimertinib): Past, Present, and Lung-itudinal Future Role in Non-Small Cell Lung Cancer 1

Col Dr G S Chaudhary | Real World Evidence Osimertinib as SoC in the management of EGFRm NSCLCПодробнее

Col Dr G S Chaudhary | Real World Evidence Osimertinib as SoC in the management of EGFRm NSCLC

Osimertinib and the FLAURA TrialПодробнее

Osimertinib and the FLAURA Trial

Новости